Estrella Immunopharma (ESLA) Total Current Liabilities (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Total Current Liabilities of $8.9 million for Q1 2026, up 108.82% year-over-year from $4.3 million in Q1 2025, and down 34.08% quarter-over-quarter from $13.5 million in Q4 2025.
Estrella Immunopharma (ESLA) Total Current Liabilities (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Total Current Liabilities for 6 consecutive years, with $8.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 108.82% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $8.9 million (up 108.82% YoY), while the FY2025 annual figure was $13.5 million, up 351.88% from the prior year.
- Total Current Liabilities slipped to $8.9 million in Q1 2026 per ESLA's latest filing, from $13.5 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $17.3 million in Q3 2023 and bottomed at $30200.0 in Q1 2022.
- Historically, Total Current Liabilities has averaged $5.1 million across 5 years, with a median of $3.0 million in 2024.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 6210.0% — and 2024, when it slumped 98.15%.
- Estrella Immunopharma's Total Current Liabilities stood at $1.1 million in 2022, then tumbled by 62.84% to $398733.0 in 2023, then jumped by 651.64% to $3.0 million in 2024, then surged by 351.88% to $13.5 million in 2025, then slumped by 34.08% to $8.9 million in 2026.
- Business Quant data shows ESLA's Total Current Liabilities at $8.9 million in Q1 2026, $13.5 million in Q4 2025, and $13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | 9.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.30 Mn |
| Mar 31, 2026 | 8.93 Mn |
| Dec 31, 2025 | 13.54 Mn |
| Sep 30, 2025 | 13.36 Mn |
| Jun 30, 2025 | 9.08 Mn |
| Mar 31, 2025 | 4.28 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Sep 30, 2024 | 2.99 Mn |
| Jun 30, 2024 | 180,701.00 |
| Mar 31, 2024 | 138,491.00 |
| Dec 31, 2023 | 398,733.00 |
| Sep 30, 2023 | 17.28 Mn |
| Jun 30, 2023 | 9.76 Mn |
| Mar 31, 2023 | 1.22 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 735,754.00 |
| Jun 30, 2022 | 154,647.00 |
| Mar 31, 2022 | 30,200.00 |
| Dec 31, 2021 | 73,154.00 |
| Sep 30, 2021 | 100,600.00 |